TY - JOUR
T1 - Antithrombotic therapy for percutaneous cardiovascular interventions
T2 - From coronary artery disease to structural heart interventions
AU - Caracciolo, Alessandro
AU - Mazzone, Paolo
AU - Laterra, Giulia
AU - Garcia-Ruiz, Victoria
AU - Polimeni, Alberto
AU - Galasso, Salvatore
AU - Saporito, Francesco
AU - Carerj, Scipione
AU - D’ascenzo, Fabrizio
AU - Marquis-Gravel, Guillaume
AU - Giustino, Gennaro
AU - Costa, Francesco
N1 - Publisher Copyright:
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2019/11
Y1 - 2019/11
N2 - Percutaneous cardiovascular interventions have changed dramatically in recent years, and the impetus given by the rapid implementation of novel techniques and devices have been mirrored by a refinement of antithrombotic strategies for secondary prevention, which have been supported by a significant burden of evidence from clinical studies. In the current manuscript, we aim to provide a comprehensive, yet pragmatic, revision of the current available evidence regarding antithrombotic strategies in the domain of percutaneous cardiovascular interventions. We revise the evidence regarding antithrombotic therapy for secondary prevention in coronary artery disease and stent implantation, the complex interrelation between antiplatelet and anticoagulant therapy in patients undergoing percutaneous coronary intervention with concomitant atrial fibrillation, and finally focus on the novel developments in the secondary prevention after structural heart disease intervention. A special focus on treatment individualization is included to emphasize risk and benefits of each therapeutic strategy.
AB - Percutaneous cardiovascular interventions have changed dramatically in recent years, and the impetus given by the rapid implementation of novel techniques and devices have been mirrored by a refinement of antithrombotic strategies for secondary prevention, which have been supported by a significant burden of evidence from clinical studies. In the current manuscript, we aim to provide a comprehensive, yet pragmatic, revision of the current available evidence regarding antithrombotic strategies in the domain of percutaneous cardiovascular interventions. We revise the evidence regarding antithrombotic therapy for secondary prevention in coronary artery disease and stent implantation, the complex interrelation between antiplatelet and anticoagulant therapy in patients undergoing percutaneous coronary intervention with concomitant atrial fibrillation, and finally focus on the novel developments in the secondary prevention after structural heart disease intervention. A special focus on treatment individualization is included to emphasize risk and benefits of each therapeutic strategy.
KW - Antiplatelet
KW - Coronary artery disease
KW - Dual antiplatelet therapy
KW - Structural heart disease
UR - http://www.scopus.com/inward/record.url?scp=85084494437&partnerID=8YFLogxK
U2 - 10.3390/jcm8112016
DO - 10.3390/jcm8112016
M3 - Review article
AN - SCOPUS:85084494437
SN - 2077-0383
VL - 8
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 11
M1 - 2016
ER -